Mankind Pharma
Mankind Pharma Completes the Sale of Mahananda Spa and Resorts, Effective February 11, 2025.
Mankind Pharma Limited is an Indian pharmaceutical company that specializes in developing, manufacturing, and marketing a wide range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as consumer healthcare products. The company’s product portfolio includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins, minerals, and respiratory therapies. Some of its notable brands include Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, and Dynaglipt, among others.
The company’s product portfolio also includes brands focused on women’s health, fertility, and critical care, with several brands in their respective therapy areas. Mankind Pharma Limited has multiple subsidiaries, including Lifestar Pharma Private Limited, Magnet Labs Private Limited, and Jaspack Industries Private Limited, among others. With a strong presence in the Indian market, the company is committed to providing high-quality healthcare solutions to its customers.
Mankind Pharma Limited’s extensive range of pharmaceutical products enables it to cater to various healthcare needs, from treating diseases to enhancing overall well-being. Its commitment to research and development ensures that its products are innovative, effective, and meet the evolving healthcare needs of its customers. The company’s substantial portfolio of brands, including some of the most popular and trusted brands in the market, has made it a respected name in the Indian pharmaceutical industry. With its focus on delivering high-quality healthcare solutions, Mankind Pharma Limited continues to work towards improving the lives of millions of people across India and beyond.
Chalet Hotels purchases Westin Spa in Uttarakhand from Mankind arm for ₹530 crore.
Chalet Hotels Ltd has acquired The Westin Resort & Spa, Himalayas in Rishikesh for ₹530 crore, subject to adjustments for net current assets. The luxury property, which has 141 rooms, was previously owned by Mahananda Spa and Resorts, a subsidiary of Mankind Pharma Ltd. The acquisition is part of Chalet’s strategy to expand its luxury footprint in premium leisure destinations.
The Westin Resort & Spa in Rishikesh started operations in January 2023 and has reported revenues of ₹71.86 crore and earnings before interest, taxes, depreciation, and amortization of ₹26.86 crore for the nine months ended December. The company generated ₹74.33 crore in revenue and ₹21.35 crore in Ebitda in FY24.
Chalet Hotels’ managing director and CEO, Sanjay Sethi, stated that the acquisition will be a key milestone in the company’s strategy to expand its footprint in the luxury and leisure segment. The company owns prominent properties such as JW Marriott Mumbai Sahar and Westin Powai, and has also acquired several other hotels and sites in recent years.
Chalet Hotels is backed by K Raheja Corp and has a portfolio of hotels and rental properties across India. The company competes with Samhi Hotels Ltd and Juniper Hotels, and has reported a 22% rise in revenue to ₹457.7 crore in Q3 FY25. However, a deferred tax liability triggered by changes in capital gains rules reduced the company’s FY25 profit, bringing its nine-month net profit down to ₹18.6 crore from ₹195.7 crore in the same period of FY24.
The acquisition of The Westin Resort & Spa, Himalayas is expected to strengthen Chalet’s leisure portfolio and further expand its luxury footprint in India. The company’s strategic move is expected to be completed by February 28, 2025.
Mankind Pharma Reports 24% Revenue Hike in Q3 FY25, According to BW Healthcare World.
Mankind Pharma, a leading pharmaceutical company in India, has reported a remarkable 24% growth in revenue for the third quarter (Q3) of the fiscal year 2022-2023 (FY25). This achievement demonstrates the company’s continued growth momentum and expanding market presence.
During Q3 FY25, Mankind Pharma’s revenue rose to ₹1,444.9 crore (approximately $181.5 million USD), showcasing the company’s resilience and ability to adapt to the evolving pharmaceutical landscape. The company’s net profit also grew by 28% to ₹432.2 crore (approximately $54.7 million USD), indicating its profitability and commitment to delivering value to its shareholders.
Mankind Pharma’s performance was driven by the strong demand for its wide range of products, including painkillers, antibiotics, cardiovascular drugs, and nutritional supplements. The company’s strategic focus on innovative products and brand expansion also contributed to its revenue growth.
In addition to its domestic sales, Mankind Pharma has made significant strides in its international operations, with a significant increase in exports to emerging markets such as the Middle East, Africa, and Southeast Asia. The company’s global expansion efforts have been supported by a robust distribution network and a dedicated team of sales professionals.
The company’s robust growth has also enabled it to strengthen its presence in the generics segment, where it has expanded its portfolio to cater to a wider range of customers. Mankind Pharma has also made strategic investments in research and development to enhance its pipeline of innovative products.
Mankind Pharma’s strong financial performance and growth momentum are a testament to its commitment to delivering high-quality products and excellent customer service. The company’s success is a reflection of its strong brand presence, innovative marketing strategies, and its ability to adapt to the evolving needs of the pharmaceutical industry.
In conclusion, Mankind Pharma’s remarkable 24% revenue growth in Q3 FY25 is a significant achievement that demonstrates the company’s resilience and ability to navigate the complexities of the pharmaceutical industry. The company’s strong performance is expected to continue, driven by its innovative products, global expansion, and strategic investments in research and development.
Anushka Sharma’s professionalism stands out, while Deepika Padukone’s demanding fee structure is a concern, according to the Co-founder of Mankind Pharma.
Rajeev Juneja, Managing Director of Mankind Pharma, recently discussed his company’s advertising strategies on a podcast. He praised Anushka Sharma for her professionalism and discipline as the brand ambassador for Prega News, crediting her army background for her down-to-earth demeanor. Juneja shared a positive experience working with Kareena Kapoor Khan, the previous brand ambassador, and expressed interest in signing Deepika Padukone as the brand’s next face. However, budget concerns have not yet led to a deal.
Juneja revealed ongoing discussions with Alia Bhatt, who is also a new mother, for the same role. Only 20-25% of the ad budget is allocated to production, including celebrity fees, with the majority spent on promoting the ad and reaching a wider audience. Juneja praised Deepika Padukone’s performance as a new mother, citing her as a potential strong ambassador for the brand.
Anushka Sharma, who has been the brand ambassador since 2020, welcomed her second child, Akaay, last year. Kareena Kapoor Khan, the previous ambassador, had a positive experience working with Juneja, which he attributes to her professional demeanor. Mankind Pharma’s collaboration with celebrities like Deepika and Alia could potentially boost their brand’s visibility and reputation.
Manforce MD sheds light on India’s distinctive condom flavor preferences, noting that Paan-flavored condoms are exclusively popular in the country.
Mankind Pharma’s MD, Rajeev Juneja, recently revealed that India has unique preferences when it comes to condom flavors, which vary across different regions. According to Juneja, paan-flavored condoms are popular in a particular state in North India, Uttar Pradesh, while jasmine-flavored condoms are the most liked in the South. He also mentioned that people in East and West India are more open to trying different flavors and are not particular about specific preferences.
Juneja also revealed that flavors like kala khatta and sabudana were merely marketing gimmicks and not actual product launches. He also confirmed that condom sales increase during Navratri in Gujarat, which is a festival that involves a lot of dancing and celebrations. A 2016 report by The Economic Times found that condom sales increase by 25-50% in pharmacies and chemists near Navratri dance venues.
Manforce, the Delhi-based arm of Mankind Pharma, claims to be India’s best-selling and largest condom brand. The company has a wide range of condom flavors, including paan, jasmine, and kala khatta, among others. Juneja’s comments provide insight into the unique preferences of different regions in India and how they impact the sales of condoms.
It’s worth noting that the Indian market is known for its diverse and regional preferences, and this is reflected in the condom market as well. Different regions have different preferences when it comes to flavors, and companies like Manforce are adapting to these preferences to stay ahead in the market.
Manforce Condoms endorses Ranbir and Janhvi Kapoor as the perfect faces for their advertisement campaign, embodying the values of responsible pleasure and safety.
Rajeev Juneja, the Managing Director and Co-Founder of Mankind Pharma, shared insights into the company’s branding strategies on a recent podcast appearance. He explained why Bollywood stars Janhvi Kapoor and Ranbir Kapoor would be ideal choices for promoting Manforce Condoms and the decision behind replacing Sunny Leone with Kartik Aaryan as the brand’s ambassador. According to Juneja, Kartik Aaryan’s relatability and appeal to a wide range of audiences made him the perfect fit for the brand’s campaign, which focuses on raising awareness about sexual health and consent among young men.
Juneja also mentioned that Janhvi Kapoor would be an excellent choice for the campaign, praising her ability to address sensitive topics and appeal to a younger audience. Ranbir Kapoor was identified as the ideal male counterpart, given his versatility and ability to connect with a diverse audience.
Mankind Pharma’s approach to selecting ambassadors is strategic, aligning the brand message with its target audience. The company prioritizes choosing relatable and versatile personalities to effectively communicate about critical health and wellness topics. Juneja also discussed the company’s other ambassadors, highlighting Anushka Sharma as an ideal representative for Prega News pregnancy test kits due to her professionalism and disciplined nature. Additionally, Deepika Padukone was mentioned as a strong contender, although the company humorously noted that her asking price may be too high.
Overall, Mankind Pharma’s brand strategies prioritize authenticity and relevance, as seen in the selection of their ambassadors. The company’s commitment to effective communication about critical health topics and wellness issues sets an example for the industry.
Mankind Pharma’s Managing Director spills the beans on which condom flavor dominates the market, with South Indians showing a special fondness for ‘jasmine’.
Here is a 400-word summary of the content:
The conversation revolves around condoms and their flavours in India, led by a conversation with Rajeev Juneja, MD of Mankind Pharma, one of India’s leading condom brands. The podcast discusses how the sales of flavoured condoms vary across different regions of the country. Juneja revealed that the most popular flavoured condoms are chocolate and strawberry, while the least popular ones are unflavoured and paan.
He mentioned that the preferences differ significantly between North and South India. While chocolate and strawberry flavoured condoms sell the most, the people of South India tend to prefer flavours like jasmine and floral scents. On the other hand, the paan flavoured condom, which has a unique blend of betel leaves, does better in places like Uttar Pradesh in North India.
The podcast also touches upon the trends in the east and west parts of India, stating that the people are more open-minded and cosmo, resulting in higher demand for different types of condoms.
Notably, Rajeev shared that sales of condoms tend to increase during certain festivals or celebrations. In the case of Gujarat, it was observed that during Navratri, condom sales surge. The podcast highlighted how important it is for individuals to have a clear understanding of their sexual health, which often results in more open discussions and more responsible attitudes towards sex and health.
Rajeev further debunked some popular myth around condom sales and revealed that flavours like kala khatta and sabudana were simply marketing gimmicks. In summary, while people have unique preferences for different flavours and varieties, the awareness about sexual health remains a pressing issue, which warrants greater education and discussion on the subject.
Kumbh CSR Initiative: A 45-Day Healthcare Crusade at Mahakumbh, Providing Thousands of Pilgrims with Free Health Screenings
Here is a summary of the content in 400 words:
Mankind Pharma, a global pharmaceutical company, has launched a 45-day healthcare mission at the Mahakumbh 2025 in Prayagraj, Uttar Pradesh, India. The initiative aims to provide essential medical services and support to thousands of pilgrims participating in the sacred gathering. The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring, and first-aid facilities.
The camp is part of Mankind Pharma’s broader Kind Care program, which focuses on enhancing community health and hygiene across India. The initiative is driven by the company’s commitment to community healthcare and its desire to ensure that pilgrims have access to essential healthcare services and products.
The camp’s comprehensive approach includes free medical consultations with qualified healthcare professionals, distribution of essential medicines and healthcare products, expert guidance on product usage and health maintenance, and specialized support for common pilgrim health concerns. Pathkind diagnostic services are also available for detailed health assessments.
Healthcare professionals at the camp report significant engagement from pilgrims, with services particularly focused on addressing the unique challenges faced during religious gatherings, including fatigue management and dietary health support. The initiative is a significant milestone in Mankind Pharma’s commitment to community healthcare and its efforts to promote the well-being of pilgrims during the Mahakumbh.
Overall, the healthcare mission is a testament to Mankind Pharma’s dedication to enhancing community health and hygiene, and its commitment to supporting the well-being of pilgrims during the Mahakumbh. The initiative is expected to have a positive impact on the health and well-being of thousands of pilgrims, and reinforces the company’s reputation as a responsible corporate citizen.
Mankind Pharma’s Q3 FY25 PAT plummets 16% to Rs. 385 Crore.
Mankind Pharma, India’s fourth-largest pharmaceutical company, has announced its financial results for the third quarter and nine months ended December 31, 2024. Despite a decline in profit after tax (PAT) by 16% to Rs. 385 crore, the company’s revenue from operations showed a significant increase of 24% year-over-year (YoY) to Rs. 3,230 crore. The domestic revenue also rose by 17% to Rs. 2,773 crore, while exports increased by 121% YoY to Rs. 457 crore.
The company’s adjusted EBITDA margin expanded by 430 basis points YoY to 27.7%, and its PAT margin remained at 11.9%. The company attributed its strong revenue growth to continued outperformance in its chronic business, a strong recovery in its over-the-counter (OTC) segment, and the consolidation of its recently acquired company, BSV.
Rajeev Juneja, Vice Chairman and Managing Director of Mankind Pharma, highlighted the company’s strategic initiatives and the successful integration of BSV, which has enabled the company to improve its productivity and adopt best practices to ensure long-term sustainable growth. He also mentioned that 2024 has been a transformative year for the company, with multiple building blocks, including a steady base business, a fast-growing specialty chronic segment, a high-potential OTC business, and a high-entry barrier super specialty portfolio of BSV.
The pharma industry is likely to experience a slow pace of profit expansion in the third quarter.
Pharmaceutical companies in India are expected to experience slower profit growth in the October-December 2024 quarter compared to the previous two quarters. According to analysts, sales growth is projected to be around 10-12% and earnings before interest, taxes, depreciation, and amortisation (EBITDA) growth of 13-15%. The growth momentum is expected to slow down due to pricing pressures and a high base effect.
Large companies such as Dr Reddy’s Laboratories (DRL) and Sun Pharma are expected to contribute to the sales growth, with DRL projected to achieve over 10% growth in its India business. Mid-sized companies like JB Pharma, Torrent Pharma, and Mankind Pharma are likely to outperform with 11-13% year-on-year (YoY) growth, driven by their chronic portfolios.
In contrast, Cipla and Zydus are expected to report relatively weaker growth of 6-8% YoY due to supply constraints and base effects. The US generics segment is projected to remain flat due to price erosion and limited significant launches.
Overall, EBITDA is expected to grow by up to 15% YoY, but margins are expected to remain flat. Cipla and DRL are likely to face margin contraction, while Sun Pharma, Lupin, and Divi’s Laboratories are expected to report strong margin expansion.
The performance of key pharma players will be closely monitored by investors, particularly with respect to their outlook and commentary on margins. Updates on DRL approval timelines for large products in the US, Biocon’s outlook following the clearance of its facilities for biosimilars, and Aurobindo Pharma’s progress towards breakeven for its Penicillin G capacity will also be crucial.